Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL, USA.
J Clin Neurosci. 2021 Jan;83:37-42. doi: 10.1016/j.jocn.2020.11.033. Epub 2020 Dec 15.
The Gamma Knife Icon (Elekta AB, Stockholm) is a cobalt-based stereotactic radiosurgery (SRS) unit to support the use of a thermoplastic mask in lieu of a rigid frame, using an onboard cone-beam CT (CBCT) and an intrafraction motion management system (IFMM). We retrospectively reviewed 124 patients treated with Gamma Knife SRS from January 2018 to December 2019 at our institution using a mask-based immobilization system. Patient and treatment characteristics were collected and summarized as well as interfraction shifts and treatment-related outcomes. This dataset includes 124 patients with an associated 358 intracranial tumors. Twenty-four patients presented with primary brain tumors, which included 14 meningiomas and 10 other histologies, with 100 patients having brain metastases. Sixty tumors were post-operative, while 298 were intact. The median dose for primary tumors was 25 Gy in 5 fractions. Median doses to metastases were 20 Gy in 1 fraction, 27 Gy in 3 fractions, and 25 Gy in 5 fractions. Median interfraction CBCT shifts were submillimeter. Median patient follow-up was 6.28 months. 91% of patients with metastases maintained local control. Our early clinical experience has demonstrated limited toxicity profiles and high patient tolerance, which suggests that mask-based Gamma Knife SRS provides a safe alternative option for frameless SRS. Patients with large target volumes where fractionation is preferred or with small target volumes in non-eloquent areas can be considered for this approach. Response rates are encouraging, and continued follow-up is necessary to investigate long-term control and survival.
伽玛刀图标(Elekta AB,斯德哥尔摩)是一种基于钴的立体定向放射外科(SRS)单元,用于支持使用热塑面罩代替刚性框架,使用机载锥形束 CT(CBCT)和分次内运动管理系统(IFMM)。我们回顾性地审查了 124 名在我们机构接受基于面罩固定系统的伽玛刀 SRS 治疗的患者,这些患者的治疗时间为 2018 年 1 月至 2019 年 12 月。收集并总结了患者和治疗特征,以及分次间移位和与治疗相关的结果。该数据集包括 124 名患者,共 358 个颅内肿瘤。24 名患者患有原发性脑肿瘤,其中包括 14 例脑膜瘤和 10 例其他组织学类型,100 例患者患有脑转移瘤。60 个肿瘤是术后的,298 个是完整的。原发性肿瘤的中位剂量为 25Gy,分 5 次给予。转移瘤的中位剂量为单次 20Gy、3 次 27Gy 和 5 次 25Gy。分次间 CBCT 移位的中位数为亚毫米。中位患者随访时间为 6.28 个月。91%的转移瘤患者保持局部控制。我们的早期临床经验表明,这种方法的毒性谱有限,患者耐受性高,表明基于面罩的伽玛刀 SRS 是一种无框架 SRS 的安全替代选择。对于需要分割的大靶体积或非优势区域小靶体积的患者,可以考虑这种方法。反应率令人鼓舞,需要继续随访以研究长期控制和生存。